The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Optimizing the manufacturing and delivery of LV20.19 CAR T-cells for R/R DLBCL and FL
Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discusses a Phase I/II trial (NCT04186520) evaluating LV20.19 CAR T-cells for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). The study focuses on optimizing the manufacturing and delivery of this CAR T-cell product. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
